Lab21 acquires NPTech Ltd and appoints corporate advisors for European M&A activity
Lab21 now has the ability to test for intolerances to over 100 food products and 50 chemicals including food colourings (E-numbers), antibiotics, anti-inflammatories and environmental chemicals. In addition, NPTech has multiple other diagnostic tests for a variety of clinical disorders including salivary tests for adrenal hormones, sex hormones and sleep disturbance together with a range of clinical biochemistry blood testing, particularly in the area of thyroid disease diagnosis and management. In addition to the range of tests, Lab21 will also benefit from the skills and experience of senior staff at NPTech, including Ron Turner who founded the company in 2002 and who will become Laboratory Director at Lab21.
Lab21 has also appointed, BDO Stoy Hayward LLP to lead its M&A activity in Europe. Peter Hemington, Corporate Finance Partner at BDO commented: "We are delighted to be chosen by Lab21 in pursuit of its aggressive M&A strategy for 2008 and excited to be working in the sectors of healthcare diagnostics and environmental monitoring."
Most read news
Topics
Organizations
Other news from the department business & finance
Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.